🎉 M&A multiples are live!
Check it out!

Iterum Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Iterum Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Iterum Therapeutics Overview

About Iterum Therapeutics

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.


Founded

2015

HQ

United States of America
Employees

9

Website

iterumtx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$60.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Iterum Therapeutics Financials

Iterum Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Iterum Therapeutics achieved revenue of n/a and an EBITDA of -$21.7M.

Iterum Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Iterum Therapeutics valuation multiples based on analyst estimates

Iterum Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$34.6M -$21.7M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$44.4M -$38.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt $7.4M $12.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Iterum Therapeutics Stock Performance

As of April 15, 2025, Iterum Therapeutics's stock price is $1.

Iterum Therapeutics has current market cap of $39.1M, and EV of $60.5M.

See Iterum Therapeutics trading valuation data

Iterum Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$60.5M $39.1M XXX XXX XXX XXX $-0.84

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Iterum Therapeutics Valuation Multiples

As of April 15, 2025, Iterum Therapeutics has market cap of $39.1M and EV of $60.5M.

Iterum Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Iterum Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Iterum Therapeutics and 10K+ public comps

Iterum Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $60.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -2.8x XXX XXX XXX
P/E -1.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Iterum Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Iterum Therapeutics Valuation Multiples

Iterum Therapeutics's NTM/LTM revenue growth is Infinity%

Iterum Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.0M for the same period.

Over next 12 months, Iterum Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Iterum Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Iterum Therapeutics and other 10K+ public comps

Iterum Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -37% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Iterum Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Iterum Therapeutics M&A and Investment Activity

Iterum Therapeutics acquired  XXX companies to date.

Last acquisition by Iterum Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Iterum Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Iterum Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Iterum Therapeutics

When was Iterum Therapeutics founded? Iterum Therapeutics was founded in 2015.
Where is Iterum Therapeutics headquartered? Iterum Therapeutics is headquartered in United States of America.
How many employees does Iterum Therapeutics have? As of today, Iterum Therapeutics has 9 employees.
Who is the CEO of Iterum Therapeutics? Iterum Therapeutics's CEO is Mr. Corey N. Fishman.
Is Iterum Therapeutics publicy listed? Yes, Iterum Therapeutics is a public company listed on NAS.
What is the stock symbol of Iterum Therapeutics? Iterum Therapeutics trades under ITRM ticker.
When did Iterum Therapeutics go public? Iterum Therapeutics went public in 2018.
Who are competitors of Iterum Therapeutics? Similar companies to Iterum Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Iterum Therapeutics? Iterum Therapeutics's current market cap is $39.1M
Is Iterum Therapeutics profitable? Yes, Iterum Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.